Abeona Therapeutics Inc

Research Abeona Therapeutics Inc (ABEO) on Bullrun: valuation model: 169.1% undervalued, market cap USD 322.59M, P/E 6.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABEO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal169.1% undervalued
• Market capUSD 322.59M
• P/E6.0
• Financial periodFY2025
• RevenueUSD 5.82M
• Net income-USD 71.18M
• Free cash flow-USD 84.30M
• Gross margin73.7%

Valuation Snapshot

Bullrun's latest valuation model marks Abeona Therapeutics Inc as 169.1% undervalued; latest market cap is USD 322.59M; P/E is 6.0.

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.

Frequently asked questions

Is Abeona Therapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Abeona Therapeutics Inc as 169.1% undervalued.

What is Abeona Therapeutics Inc's market cap?

Abeona Therapeutics Inc's market capitalization is USD 322.59M.

What is Abeona Therapeutics Inc's P/E ratio?

Abeona Therapeutics Inc's price-to-earnings (P/E) ratio is 6.0.

What does Abeona Therapeutics Inc do?

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.